Sanofi's Lantus is the top-selling product with its Lantus franchise. Merck's Januvia and Novo Nordisk's Victoza round out the top 3.
That may take a "focus on brand building that goes beyond 'ask your doctor if this drug is right for you.'"
Nobody knows what the future holds for the Affordable Care Act under the Trump administration and an emboldened Republican Congress.
"In Australia, we are the healthcare industry," he says.
Physicians do not like EHRs. That much is clear. But the vast majority have to use electronic record systems on a daily basis. What can pharma do to better give doctors what they want?
The top-selling heart drug is Merck's Zetia, which is expected to bring in about $1.68 billion in sales in 2016.
Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.
The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?
Otsuka, Astellas, Takeda, and Daiichi Sankyo share a degree of adventurousness and forward-mindedness in the digital realm.
When his mother suffered from ovarian cancer a decade ago, Robert Herjavec found himself frustrated by the quality of care she received.
The first step is to seek leadership support, she says.
The internet strongly agrees there's an artificial intelligence revolution going on, and it's come to pharma marketing.
Data scientists are a new kind of insight and analytics professional showing up in the biopharma ranks.
Here you'll find everything you need to know from MM&M's December 2016 issue, including our policy outlook for pharma in a Republican-led White House and Congress and the exclusive pipeline report.
Here's a look at 100 experimental therapies in late-stage clinical trials.
More barriers separate doctors and patients than ever before, from rising costs and time constraints to electronic health records and smartphones.
Specialty pharma ace Umer Raffat, a senior analyst at Evercore ISI, shares his 2016 postmortem and a few quick-hit predictions for 2017.
If Trump decides to go after pharma, politicians aren't likely to receive too many "How can you do this? Think about the children!" notes.
How pharma distributes information to doctors is changing as rapidly as how doctors prefer to receive and process such information
With lawmakers, patients, and physicians crying foul over pricing, drugmakers are trying to shift the narrative — with mixed results. Can a new focus on storytelling help?
As digital-health funding increases, here's how VR, nanotechnology, and 3D printing could potentially improve the value of healthcare.
Tech companies and Bernie Sanders have found the millennial audience easy to crack. Organizations in and around healthcare? Not so much.
MM&M and PRWeek editors convened to select 50 battle-tested pros who are changing the healthcare game. Find out if you made the list.
Here you'll find everything you need to know from MM&M's 50th anniversary issue, including the story behind Viagra, the death of tchotchkes, and much more.
The experimental therapy is positioned to fill a market gap in primary progressive multiple sclerosis.
MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.
The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.
Millian, a former Sanofi and Merck executive, on marketing new therapies in the MS market.
The chief creative officer at Carling Communications talks about how she learned that the best leaders are only as good as the performance of their team.
Ad pushes behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.
Here, you'll find everything you need to know about MM&M's 2016 Career and Salary Survey, including data on salaries and agency employment trends.
The agency's ambitions were fueled in part by external criticism. The barbs that stung most sharply were ones suggesting a certain indifference on the FDA's part.
When drug costs started to soar, PBMs turned to formulary exclusions — and the industry is still feeling the pinch.
Given its modern-day ubiquity, it's easy to forget that pharma DTC didn't exist until the 1980s rolled around.
The inside story on a campaign for the ages, as told by the individuals who worked on it.
Did you know that Norman Rockwell was a medical illustrator for Merck?
For some people in the industry ecosystem, the appeal of promo knickknacks endures.
And why the stories behind thalidomide, Naprosyn, AZT, cardiology stents, and Zaltrap still resonate.
The vice president of audience development talks about her days in the dot-com world and how struggling in a new role shaped her career.
They share their insights, secrets, worries, and everything else in between.
Hint: it pays to be an EVP.
"It's easy to 'fill open positions,'" Marchese says. "We've banned that phrase. If you do that, you're just checking boxes on a list."
Execs say that career prospects are better than ever. Yet data from MM&M's annual Career and Salary Survey reveals a decline in growth.
The intersection of data, technology, and medicine is rapidly changing how doctors practice, drug companies market, and patients engage with the healthcare system.
The availability of online medical information is changing the way doctors share and receive information — both among themselves and with their patients.
Diabetes is one of the most stubborn conditions to treat effectively. Drugmakers are turning to machine learning, online coaching, and gamification.
Will this payer pressure pose an existential threat to co-pay cards even though patients love them?
Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?
Amgen's osteoporosis drug Prolia is the category leader, projected to bring in $992 million in sales in 2016.
The osteoporosis drug market is bracing for the advent of potentially game-changing treatments.
Only one new osteoporosis drug has been approved over the last six years.
Read about MM&M's inaugural Hall of Femme event and the rest of the MM&M August issue.
The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.
Read the 2016 Agency Issue in its entirety.
It's unlikely that pharma will ever achieve the degree of consumer love directed at Amazon and Apple but the shift taking place will open up doors for pharma organizations.
A story about a boss giving away a woman's bonus to a man based on his breadwinning status resonated with Hall of Femme attendees.
McCann Health, the 2016 Lions Health Network of the Year, and Campaign invited top marketers and visionary artists to discuss creativity during this year's Lions Health festival.
Twitter's health team offers advice on how pharma and healthcare companies can more effectively utilize 140 characters.
Type 2 diabetes is on the rise, around the world. The IMS Institute for Healthcare Informatics breaks down diabetes prevalence in Brazil, Mexico, Saudi Arabia, the U.K., and the U.S.
Baby boomers have taken to health tech with surprising ease, opening up a wealth of opportunities for marketers savvy enough to pursue them.
While analysts predict a first-in-class appearance before the FDA by 2018, many obstacles have arisen.
Despite the arrivals of new drugs, Genentech continues to be the market leader. Its drugs, Rituxan, Avastin, and Herceptin, are the category leaders, generating a total of $9.29 billion in sales.
Interest in oncology is on the rise as the blockbuster drug era breathes its last, and this has altered marketing in cancer care.
Avanir's success with Nuedexta sparked the attention of several suitors. In 2014 the company reached a deal to be sold to Otsuka Pharmaceutical for around $3.5 billion
Read the 2016 June issue in its entirety.
Visions, challenges, and advice: Here are 100 quotes from 100 agency leaders, compiled from the MM&M Agency Issue.
Five executives from the industry's largest holding companies discuss their move away from the traditional network structure.
A number of mergers and acquisitions among healthcare agencies in 2015 and 2016 changed the landscape.
Healthcare agencies focus on freeing pharma brands from their collaboration cocoons to work with health tech companies, while squaring away access concerns.
The co-founder of Mapquest.com talks about his move from online mapping to healthcare, and what he likes most meeting with clients.
The chief planning officer of North America talks about strategy and how to tell an engaging health story.
Despite the increasing importance of the CIO post, top technology professionals still find it hard to break into the uppermost ranks at life-sciences companies.
Drugmakers and tech companies are developing wearables and using popular fitness trackers like the Fitbit in clinical trials to gain insights about Parkinson's Disease.
In partnership with inVentiv Health, MM&M found a millennial doctor to ask about her frustrations with the existing pharma marketing model to her willingness to text patients.
Besides being the right thing to do, elevating woman leaders confers a competitive edge to companies, a fact confirmed by multiple studies.
Although telehealth is still in its early stages, it's building momentum — with good reason.
Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.
A Sermo poll asked physicians: Do you feel biosimilars will prove safe and effective enough for you to prescribe them when more become available?"
Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.
Why would any CEO tolerate a corporate culture that holds people back?
- Top 25 rare disease brands, by sales
- Five things for pharma marketers to know: Monday, February 13, 2016
- Orphan drugs face criticism on prices — and from patients
- Five things for pharma marketers to know: Thursday, February 16, 2017
- Five things for pharma marketers to know: Wednesday, February 15, 2017